Evidence map›Paper›PMID 33666270›Full record

Trial reportJournal of clinical laboratory analysis2021

Probiotics ameliorates glycemic control of patients with diabetic nephropathy: A randomized clinical study.

Hongyang Jiang, Yan Zhang, Dongyan Xu, Qing Wang

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of clinical laboratory analysis, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 12 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed, 12 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 12 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Trial
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. World journal of diabetes · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Hongyang JiangChina-Japan Union Hospital Affiliated Jilin University, Changchun, China.
Yan ZhangChina-Japan Union Hospital Affiliated Jilin University, Changchun, China.
Dongyan XuChina-Japan Union Hospital Affiliated Jilin University, Changchun, China.
Qing WangChina-Japan Union Hospital Affiliated Jilin University, Changchun, China.ORCID https://orcid.org/0000-0002-3490-9365

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThis research aimed to explore the effects of probiotic administration on glycemic control and renal function in patients with diabetic nephropathy (DN).

methodsThe 101 participants were randomly divided into two treatment groups and 76 patients were included in the final analysis. In 76 patients with diabetic nephropathy of type 2 diabetes, a randomized double-blind and placebo-controlled clinical trial was conducted to evaluate the administration of 3.2 × 10

resultsAfter 12 weeks, the administration of probiotics demonstrated a significant reduction in fasting blood glucose (10.68 ± 3.24 mmol/L before vs. 7.81 ± 2.77 mmol/L after, p < 0.05), HbA1c (8.19 ± 1.60% before vs. 7.32 ± 1.20% after, p < 0.05) and mAlb/Cr (101.60 ± 22.17 mg/g before vs. 67.53 ± 20.11 mg/g after, p < 0.05), while only mAlb/Cr level was significantly lower in the probiotic group than in the placebo group after intervention (67.53 ± 20.11 mg/g vs. 87.71 ± 23.01, p < 0.05). Meanwhile, there was no significant reduction of 2 h postprandial blood glucose level (18.95 ± 5.23 mmol/L vs. 17.35 ± 6.28 mmol/L, p = 0.24) and eGFR (84.34 ± 6.97 ml/min vs. 82.8 ± 8.72 ml/min, p = 0.45) in patients before and after probiotic intake. In addition, the placebo group failed to show any significant change of these parameters.

conclusionThis clinical study revealed probiotic administration could ameliorate glycemic control of patients with diabetic nephropathy, potentiating its therapeutic potential in clinical application.

Indexed as

Glycemic ControlAlbuminuriaBlood GlucoseCreatinineDiabetic NephropathiesFastingFemaleGlomerular Filtration RateGlycated HemoglobinHumansMaleMiddle AgedPlacebosPostprandial PeriodProbioticsBlood GlucoseCreatinineGlycated HemoglobinPlacebosdiabetic nephropathyglycemic controlprobioticstype 2 diabetes mellitus

Identifiers

PMID33666270
PMCPMC8059722

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.